CytoDyn (CYDY) Total Non-Current Liabilities (2014 - 2026)

CytoDyn's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $79.2 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 12.2% year-over-year to $79.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $79.2 million (up 12.2% YoY) and the FY2025 annual result came in at $70.5 million, down 16.37% from the prior year.
• Total Non-Current Liabilities was $79.2 million for Q1 2026 at CytoDyn, down from $85.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $126.2 million in Q1 2024 and bottomed at $69.4 million in Q3 2025.
• A 5-year average of $93.7 million and a median of $84.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 22288.22% — and 2024, when it plunged 44.24%.
• CytoDyn's Total Non-Current Liabilities stood at $123.6 million in 2022, then rose by 0.0% to $123.6 million in 2023, then plunged by 42.8% to $70.7 million in 2024, then grew by 20.39% to $85.1 million in 2025, then declined by 6.93% to $79.2 million in 2026.
• Business Quant data shows CYDY's Total Non-Current Liabilities at $79.2 million in Q1 2026, $85.1 million in Q4 2025, and $69.4 million in Q3 2025.